New targeted drug trial launches for Hard-to-Treat cancers
Disease control
Not yet recruiting
This early-stage study is testing a new targeted drug called CGT6297 in adults with advanced solid tumors that have a specific genetic change called a PIK3CA mutation. The main goals are to find a safe dose and see if the drug shows early signs of helping to shrink tumors. The st…
Phase: PHASE1 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC